Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMI 9523

Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523; LMWF 5A

Latest Information Update: 20 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Antirheumatics; Dipeptides; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Immunomodulators; Inflammation mediator inhibitors; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Preclinical Chronic obstructive pulmonary disease
  • Research Eye disorders
  • No development reported Crohn's disease; Inflammation; Neurological disorders; Rhinitis

Most Recent Events

  • 12 Dec 2018 Ampio Pharmaceuticals plans an additional clinical trial for Osteoarthritis under a Special Protocol Assessment (SPA)
  • 07 Nov 2018 Efficacy and adverse events data from a phase III open-label extension study in Osteoarthritis released by Ampio Pharmaceuticals
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Crohn's-disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top